Bath salt use: A case report and review of the literature

Journal of Dual Diagnosis

Volumn 8, Issue 3, 2012, Pages 250-256

  McClean, Jacob M ^a   Anspikian, Ara ^b   Tsuang, John W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

amphetamine; bath salts; cathinone; MDPV; mephedrone; methcathinone; methylone; psychosis; schizophrenia

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; AMPHETAMINE; BATH SALT; CATHINONE; COCAINE; METHYLONE; OLANZAPINE; PYROVALERONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ALCOHOLICS ANONYMOUS; BEHAVIOR CONTROL; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DELIRIUM; DISEASE COURSE; DRUG DEPENDENCE; DRUG INTOXICATION; HALLUCINATION; HUMAN; MALE; METHAMPHETAMINE DEPENDENCE; NEUROTOXICITY; POISON CENTER; PREVALENCE; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 84865272591     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2012.697447     Document Type: Review

References (58)

1. Adebamiro, A., & Perazella, M. A. (2102.) Recurrent acute kidney injury following bath salts intoxication. American Journal of Kidney Disease, 59(2), 273-275. doi:10.1053/j.ajkd.2011.10.012
2. Al-Hebshi, N. N., & Skaug, N. (2005). Khat (Catha edulis)-An updated review. Addiction Biology, 10, 299-307. (Pubitemid 41759263)
3. Ali, W. M., Al Habib, K. F., Al-Motarreb, A., Singh, R., Hersi, A., Al Faleh, H., . . . Al Suwaidi, J. (2011). Acute coronary syndrome and khat herbal amphetamine use: An observational report. Circulation, 124, 2681-2689. doi:10.1161/CIRCULATIONAHA.111.039768
4. Ali, W. M., Zubaid, M., Al-Motarreb, A., Singh, R., Al-Shereiqi, S. Z., Shehab, A., . . . Al Suwaidi, J. (2010). Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clinical Proceedings, 85(11), 974-980. doi:10.4065/mcp.2010.0398
5. Angoa-Perez, M., Kane, M. J., Francescutti, D. M., Sykes, K. E., Shah, M. M., Mohammed, A. M., . . . Kuhn, D. M. (2011). Mephedrone, an abused psychoactive component of "bath salts" and methamphetamine congener, does not cause neurotoxity to dopamine nerve endings of the striatum. Journal of Neurochemistry. doi:10.1111/j.1471-4159.2011.07632.x
6. Antonowicz, J. L., Metzger, A. K., & Ramanujam, S. L. (2011). Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: Two cases. General Hospital Psychiatry, 33(6), 640.e5-640.e6.
7. Baumann, M. H., Ayestas, M. A. Jr., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., . . . Cozzi, N. V. (2011). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology, 37(5), 1192-1203. doi:10.1038/npp.2011.304
8. Breneisen, R., Fisch, H. U., Koelbing, U., Geisshusler S., & Kalix, P. (1990). Amphetamine-like effects in humans of the khat alkaloid cathinone. British Journal of Clinical Pharmacology, 30, 825-828.
9. Brandt, S. D., Sumnall, H. R, Measham, F., & Cole, J. (2010). Analyses of second-generation 'legal highs' in the UK: Initial findings. Drug Testing and Analysis, 2(8), 377-382.
10. Bruno, R.,Matthews, A. J., Dunn, M., Alati, R., McIlwraith, F., Hickey, S., . . . Sindicich, N. (2011). Emerging psychoactive substance use among regular ecstasy users in Australia. Drug and Alcohol Dependence. Advance online publication. doi:10.1016/j.drugalcdep.2011.11.020
11. Brunt, T. M., Poortman, A., Niesink, R. J., & van den Brink, W. (2010). Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology, 25, 1543.
12. Brunt, T. M., Koeter, M. W., Niesink, R. J. M., & van den Brink, W. (2011). Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology, 220(4), 751-762. doi:10.1007/s00213-011-2529-4
13. Carhart-Harris, R. L., King, L. A., & Nutt, D. J. (2011). A Web-based survey on mephedrone. Drug and Alcohol Dependence, 118, 19-22. doi:10.1016/j.drugalcdep.2011.02.011
14. Carey, K. B., Carey, M. P., Maisto, S. A., & Purnine, D. M. (2002). The feasibility of enhancing psychiatric outpatients' readiness to change their substance use. Psychiatric Services, 53, 602-608. (Pubitemid 34454181)
15. Centers for Disease Control and Prevention. (2011). Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. Morbidity and Mortality Weekly Report, 60(19), 624-627.
16. Coppola, M., & Mondola, R. (2012). 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicology Letters, 208, 12-15.
17. Dargan, P. I., Albert, S., & Wood, D. M. (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM: An International Journal of Medicine, 103, 875-879. doi:10.1093/qjmed/hcq134
18. De Paoli, G., Brandt, S. D., & Pounder, D. J. (2011). Mephedrone. Banned but still available on the Internet. British Medical Journal, 342, d1629. doi:10.1136/bmj.d1629.
19. Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section (DEA). (2011). Khat. Retrieved from http://www.deadiversion.usdoj.gov/drugs concern/khat.pdf
20. Durham, M. (2011). Ivory wave: The next mephedrone? Emergency Medical Journal, 28, 1059-1060.
21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2011). Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. Lisbon, Portugal: The Publications Office of the European Union. Retrieved from http://www.emcdda.europa.eu/ attachements.cfm/att 116646 EN TDAK 11001ENC WEB-OPTIMISED%20FILE.pdf
22. Freeman, T. P., Morgan, C. J. A., Vaughn-Jones, J., Hussain, N., Karimi, K., & Curran, H. V. (2012). Cognitive and subjective effects of mephedrone and factors influencing use of a "new legal high." Addiction. Advance online publication. doi:10.1111/j.1360-0443.2011.03719.x
23. Gebissa, E. (2010). Khat in the Horn of Africa: Historical perspectives and current trends. Journal of Ethnopharmacology, 132, 607-614.
24. Griffiths, P., Lopez, D., Sedefov, R., Gallegos, A., Hughes, B., Noor, A., & Royuela, L. (2010). Khat use and monitoring drug use in Europe: The current situation and issues for the future. Journal of Ethnopharmacology, 132, 578-583.
25. Hadlock, G. C., Webb, K. M., McFadden, L. M., Chu, P. W., Ellis, J. D., Allen, S. C., . . . Fleckenstein, A. E. (2011). 4-Methylmethcathinone (mephedrone): Neuropharmacological effects of a designer stimulant of abuse. Journal of Pharmacology and Experimental Therapeutics, 339(2), 530-536.
26. Hassan, N. A., Gunaid, A. A., & Murray-Lyon, I. M. (2007). Khat (Catha edulis): Health aspects of khat chewing. East Mediterranean Health Journal, 13, 706-718. (Pubitemid 47091277)
27. James, D., Adams, R. D., Spears, R., Cooper, G., Lupton, D. J., Thompson, J. P., & Thomas, S. H. L. (2011). Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emergency Medicine Journal, 28, 686-689.
28. Kasick, D. P., McKnight, C. A., & Klisovic, E. (2012). "Bath salt" ingestion leading to severe intoxication delirium: Two cases and a brief review of the emergence mephedrone use. American Journal of Drug and Alcohol Abuse, 38(2), 176-180. doi:10.3109/00952990.2011.643999
29. Kehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., & Yoshitake, T. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. British Journal of Pharmacology, 164(8), 1949-1958.
30. Kelly, J. P. (2011). Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis, 3(7-8), 439-453.
31. Kikura-Hanajiri, R., Kawamura, M., Saisho, K., Kodama, Y., & Yukihiro, G. (2007). The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. Journal of Chromatography B, 855, 121-126. (Pubitemid 47212020)
32. Klein, A., &Metaal, P. (2010). A good chew or good riddance-How to move forward in the regulation of khat consumption. Journal of Ethnopharmacology, 132, 584-589.
33. Kriikku, P., Wilhelm, L., Schwarz, O., & Rintatalo, J. (2011). New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Science International, 210, 195-200.
34. Lea, T., Reynolds, R., & DeWit, J. (2011). Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug and Alcohol Review, 30(4), 438-340. doi:10.1111/j.1465-3362.2011.00288.x
35. Levin, O. S. (2005). "Ephedron" encephalopathy [article in Russian]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 105(7), 12-20.
36. Li, S., Campbell, B. L., & Katz, J. L. (2006). Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. The Journal of Pharmacology and Experimental Therapeutics, 317, 1088-1096. (Pubitemid 43764112)
37. Marsden, J., Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., & Puchnarewicz, M. (2011).Mephedrone: Use, subjective effects and health risks. Addiction, 106, 1991-1996.
38. Meyer, M. R.&Maurer, H. H. (2010).Metabolism of designer drugs of abuse: An updated review. Current Drug Metabolism, 11, 468-482.
39. McElrath, K., & O'Neill C. (2011). Experiences with mephedrone pre-and post-legislative controls: Perceptions of safety and sources of supply. International Journal of Drug Policy, 22, 120-127.
40. Mixmag. (2010). Mephedrone: Meet the UK's favourite new drug. Retrieved from http://www.mixmag.net/words/news/mephedrone%3Ameet-the-uks-favourite-new- drug
41. Morris, K. (2010). UK places generic ban on ephedrine drug family. Lancet, 375(9723), 1333-1334.
42. Mugele, J., Nañagas, K. A.,&Tormoehlen, L.M. (2012). Serotonin syndrome associated with MDPV use: Acase report. Annals of Emergency Medicine. Advance online publication. doi:10.1016/j.annemergmed.2011.11.033
43. National Drug Intelligence Center (NDIC). (2011). Situation report: Synthetic cathinones (bath salts): An emerging domestic threat (Product Number 2011-S0787-004). Retrieved from http://www.justice.gov/ndic/pubs44/44571/44571p. pdf
44. Penders, T. M., & Gestring, R. (2011). Hallucinatory delirium following use of MDPV: "Bath salts." General Hospital Psychiatry, 33(5), 525-526.
45. PsychonautWebMapping Research Group. (2009). Mephedrone report. London, England: Institute of Psychiatry, King's College London.
46. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA: Journal of the American Medical Association, 264(19), 2511-2518.
47. Spiller, H. A., Ryan, M. L., Weston, R. G., & Jansen, J. (2011). Clinical experience with analytical confirmation "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical Toxicology, 49, 499-505.
48. Sogawa, C., Sogawa, N., Ohyama, K., Kikura-Hanajiri, R., Goda, Y., Sora, I., & Kitayama, S. (2011). Methylone and monoamine transporters: Correlation with toxicity. Current Neuropharmacology, 9, 58-62.
49. Stephens, A., Logina, I., Liguts, V., Aldins, P., Eksteina, I., Platkaji, A., . . . Donaghy, M. (2008).Aparkinsonian syndrome inmethcathinone users and the role of manganese. The New England Journal of Medicine, 358(10), 1009-1017. (Pubitemid 351347100)
50. Toth, A. R., Hideg, A., & Institoris, L. (2011).Mephedrone: An old-new drug of abuse. Orvost Hetilap, 152(30), 1192-1196.
51. U.S. Department of Justice, Drug Enforcement Administration (USDEA). (2011). Schedules of controlled substances: Temporary placement of three synthetic cathinones into Schedule I. Federal Register/Vol. 76, No. 204/Friday, October 21, 2011/Rules and Regulations.
52. Varlibas, F., Delipoyraz, I., Yuksel, G., Filiz, G., Tireli, H., & Gecim, N. O. (2009). Neurotoxicity following chronic intravenous use of "Russian Cocktail." Clinical Toxicology, 47, 157-160.
53. Vardakou, I., Pistos, C., & Spiliopoulo, C. H. (2011). Drugs for youth via Internet and the example of mephedrone. Toxicology Letters, 201, 191-195.
54. Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., & Schifano, F. (2010). Mephedrone, new kid for the chop? Addiction, 106, 154-161. doi:10.1111/j.1360-0443.2010.03130.x
55. Winstock, A. R., Marsden, J., & Mitcheson, L. (2010). What should be done about mephedrone? British Medical Journal, 340, c1605. doi:10.1136/bmj. c1605
56. Winstock, A., Mitcheson, L., & Marsden, J. (2010). Mephedrone: Still available and twice the price. Lancet, 376, 1537.
57. Wood, D. M., Davies, S., Greene, S. L., Button, J., Holt, D. W., Ramsey, J., & Dargan, P. I. (2010a). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology, 48, 924-927.
58. Wood, D. M.,Greene, S. L.,&Dargan, P. I. (2010b).Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Medicine Journal, 28, 280-282. doi0:10.1136/emj.2010.092288